Skip to main content
Premium Trial:

Request an Annual Quote

Takara Pays Lynx $3M in Modification of Licensing Agreement

NEW YORK, Aug. 5 (GenomeWeb News) - Lynx Therapeutics of Hayward, Calif., said today that Takara Bio of Japan has paid it $3 million in a modification of the two companies' technology licensing agreement.

 

Under the modification of the agreement, which was originally signed in 2000 and expanded earlier this year, Takara will now have the exclusive, royalty-free right to use Lynx's technologies in China, Korea, and Japan.

 

Takara will also be relieved of its obligation to pay Lynx, $2 million in 2003 and 2004, along with royalties, and has obtained three of Lynx' Massively Parallel Signature Sequencing, or MPSS, instruments, in addition to the two it already owns.

 

The modified agreement also relieves Takara, which owns 13.5 percent of Lynx outstanding common stock, of an obligation under the original agreement to make additional equity investments in Lynx.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.